Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminophylline for Reversal of Complete Heart Block in Inferior Wall MI
NCT05666219Phase 4Withdrawn
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of aminophylline in complete heart block (CHB), sponsored by National Institute of Cardiovascular Diseases. Primary endpoint: Reversal of complete heart block. Planned start Dec 2022; status: withdrawn.
02
Drugs
aminophylline
03
Conditions
complete heart block (CHB)
Beyond the preview
Go deeper on NCT05666219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666219.